Related Experiment Video

Updated: May 11, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

A novel 2-pyrone derivative, BHP, impedes oncogenic KRAS-driven malignant progression in breast cancer

Rae-Kwon Kim1, Yongjoon Suh, Eun-Jung Lim

  • 1Department of Chemistry, Research Institute for Natural Sciences, Hanyang University, Seoul 133-791, Republic of Korea.

Cancer Letters
|May 28, 2013
PubMed

Insights

A new compound, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one (BHP), effectively blocks KRAS-driven breast cancer progression. BHP targets oncogenic KRAS signaling, suppressing tumor cell migration, invasion, and resistance to treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Medicinal Chemistry

Background:

  • Elevated KRAS expression drives cancer progression, but KRAS-targeting therapies have shown limited success.
  • KRAS mutations represent a significant challenge in cancer treatment, particularly in breast cancer.

Purpose of the Study:

  • To investigate the potential of a novel 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one (BHP), as a therapeutic agent against KRAS-driven breast cancer.
  • To elucidate the mechanism by which BHP affects KRAS signaling pathways and cancer cell phenotypes.

Main Methods:

  • Treatment of MDA-MB231 breast cancer cells (carrying oncogenic KRAS) with BHP.
  • Assessment of cell migration, invasion, and epithelial-mesenchymal transition (EMT) markers.
  • Forced expression of oncogenic KRAS in MCF10A, MCF7, and SK-BR3 cells, followed by BHP treatment.
  • Analysis of BHP's effect on KRAS-Raf-1 interaction and downstream signaling pathways (PI3K/AKT, ERK).

Main Results:

  • BHP suppressed migratory and invasive properties and EMT in MDA-MB231 cells.
  • BHP sensitized cancer cells to conventional anticancer treatments.
  • BHP effectively blocked KRAS-induced malignant phenotypes, including migration, invasion, EMT, and drug resistance, in other breast cell lines.
  • BHP inhibited the interaction between KRAS and Raf-1 in a concentration-dependent manner, disrupting downstream PI3K/AKT and ERK signaling.

Conclusions:

  • The α-pyrone derivative BHP demonstrates potent anticancer activity against KRAS-driven breast cancer.
  • BHP functions by targeting oncogenic KRAS signaling pathways, offering a potential new therapeutic strategy for intractable KRAS-mutant cancers.
Keywords:
Epithelial–mesenchymal transitionInvasionMalignant progressionMigrationRas signaling pathwayα-Pyrone derivative

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...